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Melanoma is one of the aggressive cancer types. Mutations
that lock the BRAF protein in an active state may cause excessive
signaling in the pathway, leading to uncontrolled cell growth and
survival. Primarily among the BRAF mutations observed in mela-
noma, over 90% are supposed to be at codon 600, resulting in sub-
stitution of glutamic acid for valine, V600E (T > A transversion)
located in exon 15, BRAFV600E. Of particular interest is BRAF neg-
ative melanoma. This type of melanoma is not sensitive to BRAF
inhibitors and approaches to therapy require further study. We
aimed to investigate the frequency of BRAF V600 mutations in 80
patients with primary melanoma and determine the relationship
between mutations and clinical/pathologic features. Genomic
DNA was extracted from biopsy specimens with prevalent per-
centage of tumor cells by DNA-sorb B isolation kit (Amplisense,
Russia). BRAF V600E mutation was estimated by real-time PCR-
based assay for the BRAF V600E mutation allele-specific DNA test
(BioLink, Russia). Breslow thickness was assessed by applying
commercial Infinity Capture, Infinity Analyze Software. The
lymphocytic infiltration was determined in all tumors and
classified as ‘‘brisk”, ‘‘nonbrisk”, and ‘‘absent” according to criteria
established by Clark et al. Tumor infiltrating lymphocytes (TIL)
were identified as lymphocytes within tumor nodes. ‘‘Brisk”
infiltrate was determined in case of a diffuse presence of lympho-
cytes within tumor, ‘‘non-brisk” infiltrate was in focal location of
lymphocytes and ‘‘absent” if no lymphocytes were present in a
tumor. Mitotic activitywas determined asmitotic count on 10 high
power fields. For all patients, clinical and pathologic features
were tested for significant association with BRAF V600E mutation
status using simple cross tabulations, Fisher’s exact test, Pearson’s
v2 test, and/or non-parametric Mann–Whitney U test. The P
values lower 0.05 were considered as significant. BRAF V600E
mutation was detected in 41.25% of tested tumours. Patients with
BRAF-mutant and non-BRAF mutant melanoma were matched by
age and gender. Superficial spreading melanomawas observed in
66.2% of patients with wild-type BRAF, nodular melanoma in
21.2%, both lentigo-melanoma and acral-lentiginous melanomain
6.3% and mucosal melanoma in 1 3.0% of patients. In wild-type
BRAF melanoma patients, 59.7% tumors had ‘‘brisk” infiltrate,
14.8% – ‘‘non-brisk”, and 12 25.5% had no infiltrate. There was
no found correlation between BRAF status and tumor localization,
clinico-pathological type of tumor, TIL status, Breslow thickness
and mitotic rate. However, when cases were stratified by age, it
was revealed that melanoma patients aged above 80 years
were preferentially BRAF-negative (p < 0.05). BRAF-negative
melanomas occurred significantly more frequent in superficial
spreading type of the tumor. The localization of melanomas was
different between the patients with mutant BRAF status and
patients with wild-type BRAF status with regard to elderly and
younger patients (p = 0.03). The mean age was 54.4 years for
patients with BRAF-mutant melanoma localized on the trunk
and 63.7 years for patients with wild-type BRAF. In our study, no
relationship between BRAF status and tumor localization was
found, although tumors localized on extremities had tendency
to be BRAF V600E negative. Although our study revealed no any
other associations between melanoma prognostic markers and
BRAF V600E status, melanoma mutational profiling identification
may be important for predicting a worse prognosis in certain
patients.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.002
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During cancer development, tumor cells gain the ability to
invade and metastasize. Individual cells use alternative migration
modes based on different cellular mechanisms. One of them is
mesenchymal motility mode which is driven by leading edge
protrusion in the form of filopodia or/and lamellipodia based on
Arp2/3 dependent actin polymerization. Mesenchymal motility
depends on formation of cell-substrate adhesions, activity of
matrix metalloproteases (MMPs) and on activity of small
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GTPaseRac. Another mode is amoeboid motility, which involves
formation of blebs – hollowmembrane protrusions extruded from
the cell surface by actin-myosin contraction. Amoeboid motility
does not need both pronounced cell-substrate adhesions and
MMPs activity and required increase of activity of small GTPase
Rho. Fibroblasts and scattered epithelial cells migrate by mes-
enchymal mode, while blood cells – lymphocytes or macrophages
mainly use amoeboid mode for migration. It was shown that
some treatments cause transition from one motility mode to
another. Switches from mesenchymal to amoeboid motility and
opposite are called mesenchymal-amoeboid transition (MAT)
and amoeboid -mesenchymal transition (AMT) respectively. The
ability of cells for such transitions was named as plasticity of
migration. We compared the plasticity of migration of normal
and tumor cells. To study plasticity of mesenchymally migrated
cells (MAT) we choose fibrosarcoma cells HT1080 as tumor and
non-transformed subcutaneous fibroblasts 1036 as normal
counterpart. To study AMT we choose a few lines of myeloid
leukemia THP1, K562, KG1 in contrast to normal leukocytes
obtained from healthy donors. We showed that fibrosarcoma cells
in opposite to non-transformed fibroblasts could undergo MAT
under treatments, which limited mesenchymal migration. Two
approaches to limit mesenchymal motility of cells were used.
One was decrease of substrate adhesiveness by treatment of
coverslips with PolyHema solutions, which simulated the
alteration of environmental conditions during cell migration.
The other approach was influence on cellular pathways regulated
cell motility. We used CK666, the inhibitor of Arp2/3 activity,
which stopped actin polymerization and thus lamellipodia
formation through Arp2/3 dependent mechanism. We showed
that under both treatments the fraction of tumor cells switched
from lamellipodia formation to blebbing and thus underwent
MAT, while in non-transformed fibroblasts these treatments led
to retraction of lamellipodia and significant failure of motility.
Both leukemia cells and leucocytes of healthy donors showed
blebs formation (amoeboid motility). We induced transition to
mesenchymal motility by alteration of culture conditions. The
first approach was the increase of substrate adhesiveness by
treatment with fibronectin. Another way was to inhibit of small
GTPase Rho activity. In result of both treatments, leukemia cells
switched from amoeboid to mesenchymal motility (underwent
AMT), but leucocytes of healthy donor could not do such
transition. For the first time it was shown that AMT is features
of leukemia cells but not leucocytes from healthy donors. Both
MAT and AMT are reversible, meaning that cells exhibiting
plasticity could change motility mode in dependence on
environment. Our results demonstrate that tumor cells of differ-
ent origin could transit from one mode of motility to another
and normal cells could not undergo such transitions. We also
investigate the effectiveness of amoeboid and mesenchymal
motility during migration in different environments. It was
shown that the mesenchymal motility is more effective for 2D
migration, while the amoeboid motility is more effective in 3D
conditions. During dissemination, cells go beyond the borders of
original tissues and pass through environment with different
properties. The plasticity of migration triggered by alteration of
entire or internal conditions dramatically increases ability of cells
to disseminate. The ability of tumor cells to plasticity permits
them to choose optimal mode for migration, thus leading to
metastasis development.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.003
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Background: Tamoxifen, a selective estrogen receptor modula-
tor, remains a standard of endocrine therapy for estrogen recep-
tor alpha (ERa) positive breast cancer (Goldhirsch et al., 2013).
Despite well-known advantages of tamoxifen treatment, approx-
imately one third of patients experience a relapse or disease
progression due to tamoxifen resistance (Osborne et al., 2011).
Identification of additional molecular markers associated with
both ER genomic and non-genomic pathways could be very useful
to help identify patients who will likely benefit from such endo-
crine treatment. The aim of the present study was to evaluate
the influence of the distribution pattern of ERa expression as well
as ESR1, TGF-bR1 and IGF-1R single nucleotide polymorphisms
(SNPs) and the expression of growth factors receptors on disease
progression in breast cancer patients of Russian Western Siberian
population treated by adjuvant tamoxifen.
Materials and methods: Formalin-fixed paraffin-embedded
tumor tissue samples were retrospectively collected from 97
hormone receptor-positive breast cancer patients treated with
adjuvant tamoxifen at the Tomsk Cancer Research Institute.
Genotypes for ESR1 +30T>C (rs2077647), ESR12014G>A
(rs2228480), IVS7+24G>A (rs334354) and IGF-1R (rs2016347) SNPs
were detected by a TaqMan assay. The distribution patterns of
ERa expression and EGFR, TGF-bR1, IGF-1R protein expression
were determined using the immunohistochemistry. Patients
who developed distant metastasis or recurrence after tamoxifen
treatment during the follow-up period were defined as tamoxifen
resistance (TR) group, while distant metastasis-free patients were
analyzed as tamoxifen sensitive (TS) group.
Results: We found that the heterogeneous distribution of ERa
expression was statistically significant related with poor progno-
sis of tamoxifen treated patients (p = 0.021). Similarly, we showed
high EGFR expression in TR group compared to TS patients (80.0%
vs. 41.9% respectively, p = 0.009). Additionally, EGFR expression
and distribution pattern of ERa expression were significantly
associated with response to tamoxifen and this association
remained significant in both univariate and multivariate analysis.
Our results demonstrate that the ESR12014A mutant allele
carriers were more prevalent in TR patients than in TS group
(26.3% vs. 8.0%, respectively, p = 0.009). Concerning the IGF-1R
polymorphism, we found that TT homozygous carriers were more
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